GNE-317 50 mg | 99.42%
TargetMol
GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).
More Information Supplier PageGNE-317
Search Results
GNE-317 10 mg | 99.42%
TargetMol
GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).
More Information Supplier PageGNE-317
(R)-baclofen 25 mg | 99.43%
TargetMol
(R)-baclofen (STX209), a derivative of gamma-aminobutyric acid, is commonly utilized for the treatment of spasticity.
More Information Supplier Page(R)-baclofen
Tosedostat 1 mg | Purity Not Available
TargetMol
CHR-2797 is an orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. CHR-2797 is converted intracellularly into a poorly membrane-permeable active metabolite (CHR-79888) which inhibits the M1 family of aminopeptidases, particularly puromycin-sensitive aminopeptidase (PuSA), and leukotriene A4 (LTA4) hydrolase; inhibition of these aminopeptidases in tumor cells may result in amino acid […]
More Information Supplier PageTosedostat
Desvenlafaxine succinate hydrate 500 mg | Purity Not Available
TargetMol
Desvenlafaxine succinate hydrate is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI).
More Information Supplier PageDesvenlafaxine succinate hydrate
Desvenlafaxine succinate hydrate 100 mg | Purity Not Available
TargetMol
Desvenlafaxine succinate hydrate is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI).
More Information Supplier PageDesvenlafaxine succinate hydrate
Desvenlafaxine succinate hydrate 50 mg | Purity Not Available
TargetMol
Desvenlafaxine succinate hydrate is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI).
More Information Supplier PageDesvenlafaxine succinate hydrate
Desvenlafaxine succinate hydrate 10 mg | Purity Not Available
TargetMol
Desvenlafaxine succinate hydrate is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI).
More Information Supplier PageDesvenlafaxine succinate hydrate
PHA-665752 100 mg | 99.35%
TargetMol
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
More Information Supplier PagePHA-665752
Tivantinib 200 mg | 99.95%
TargetMol
Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
More Information Supplier PageTivantinib
